Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Altimmune management will host a conference call and webcast with a slide presentation beginning at
Conference Call Information:
|International Dial-in:||(918) 922-3148|
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor and Media Contact:
Chief Financial Officer
Source: Altimmune, Inc